Wednesday, January 16 | 2:00 - 3:05 pm
PepTalk Perspectives: Point-Counterpoint Discussions
“Change is inevitable. Progress is a choice.”
“Permanence, perseverance, and persistence in spite of all obstacles, discouragements, and impossibilities: It is this, that in all things distinguishes the strong soul from the weak.”
IT IS HUMAN NATURE to resist change, especially in the ultraconservative biopharmaceutical industry. Despite this, there is a corresponding desire to make things better whenever possible. However, do advances in technology always result in progress? By design, PepTalk’s eight Pipelines cover a range of topics from R&D discovery to product development where exciting new developments are presented, each with the potential to have significant impact on the discovery and product development lifecycle. Are these changes universally positive? The positive-negative viewpoint may differ depending on a company’s or individual’s perspective.
In thought-provoking point-counterpoint discussions, panelists address the impact and implications of new technology and other advances on accelerating biopharma product development, with topics including:
» Dealing with Regulatory Reform
» Pros and Cons of Accelerating Time to Market
» Impact of Implementing New Technologies
» Impact of Adopting New Therapies and Targets
» What, Where, and When Impact of Big Data
Howard Levine, PhD, President and CEO, BioProcess Technology Consultants
Zhimei Du, PhD, Director, Bioprocess & Clinical Manufacturing, Merck
Lorenz Mayr, PhD, CTO, GE Healthcare Life Sciences
Additional Conference Keynote Speakers
Tara Arvedson, PhD, Director, Oncology Research, Amgen, Inc.
Steven Cramer, PhD, William Weightman Walker Professor, Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute
Matthew P. DeLisa, PhD, William L. Lewis Professor, Chemical & Biomolecular Engineering, Cornell University
Rakesh Dixit, PhD, Vice President and Global Head, Translational Sciences-Biologics Safety Assessment, MedImmune, LLC
Jennifer Dumont, PhD, Executive Director, Medical Affairs, Bioverativ, Inc.
Isidro Hotzel, PhD, Senior Scientist, Genentech
Alan K. Hunter, PhD, Director, Purification Process Sciences, MedImmune, LLC
Paul Imbach, MD, Professor, Ped. Oncology/Hematology, University of Basel, Switzerland
Stephen Albert Johnston, PhD, CEO, Calviri, Inc.; Director and Professor, Biodesign Center for Innovations in Medicine, Arizona State University
Alexander (Sasha) Kabanov, PhD, DrSci, Distinguished Professor, Eshelman School of Pharmacy, University of North Carolina and Chapel Hill
Satoshi Ohtake, PhD, Senior Director, Pharmaceutical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer, Inc.
Takeshi Omasa, PhD, Professor, Department of Material and Life Science, Graduate School of Engineering, Osaka University
Palani Palaniappan, PhD, Head, Tech Ops & Andover Site, Sarepta Therapeutics
Bernhard Palsson, PhD, Galletti Professor, Bioengineering; Principal Investigator, Systems Biology Research Group, Bioengineering; Professor, Pediatrics, University of California, San Diego
Joël Richard, PhD, Vice President, Peptides, CMC & Engineering, Ipsen
Christian Schöneich, PhD, Takeru Higuchi Distinguished Professor and Chair, Department of Pharmaceutical Chemistry, The University of Kansas
Mohammad Tabrizi, PhD, Director, Biologics PPDM, Merck Research Laboratories Palo Alto
Kerstin Walke, PhD, Head, Pharmaceutical Development Biologicals, Boehringer Ingelheim